Visual-Statistical Interpretation of ¹⁸F-FDG-PET Images for Characteristic Alzheimer Patterns in a Multicenter Study: Inter-Rater Concordance and Relationship to Automated Quantitative Evaluation

References

1. 1.↵
   1. Silverman DH,
   2. Small GW,
   3. Chang CY,
   4. et al

   . Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120–27

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Mosconi L,
   2. Perani D,
   3. Sorbi S,
   4. et al

   . MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004;63:2332–40

   CrossRef
3. 3.↵
   1. Yuan Y,
   2. Gu ZX,
   3. Wei WS

   . Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol 2009;30:404–10

   Abstract/FREE Full Text
4. 4.↵
   1. Herholz K,
   2. Salmon E,
   3. Perani D,
   4. et al

   . Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG-PET. Neuroimage 2002;17:302–16

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Herholz K,
   2. Westwood S,
   3. Haense C,
   4. et al

   . Evaluation of a calibrated ¹⁸F-FDG-PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med 2011;52:1218–26

   Abstract/FREE Full Text
6. 6.↵
   1. Ng S,
   2. Villemagne VL,
   3. Berlangieri S,
   4. et al

   . Visual assessment versus quantitative assessment of ¹¹C-PIB PET and ¹⁸F-FDG-PET for detection of Alzheimer's disease. J Nucl Med 2007;48:547–52

   Abstract/FREE Full Text
7. 7.↵
   1. Tolboom N,
   2. van der Flier WM,
   3. Boverhoff J,
   4. et al

   . Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [¹¹C]PIB and [¹⁸F]FDDNP PET images. J Neurol Neurosurg Psychiatry 2010;81:882–84

   Abstract/FREE Full Text
8. 8.↵
   1. Rabinovici G,
   2. Rosen H,
   3. Alkalay A,
   4. et al

   . Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011;77:2034–42

   CrossRef
9. 9.↵
   1. Iwatsubo T

   . Japanese Alzheimer's Disease Neuroimaging Initiative: present status and future. Alzheimers Dement 2010;6:297–99

   CrossRefPubMed
10. 10.↵
    1. McKhann G,
    2. Drachman D,
    3. Folstein M,
    4. et al

    . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–44

    CrossRefPubMed
11. 11.↵
    1. Ikari Y,
    2. Nishio T,
    3. Makishi Y,
    4. et al

    . Head motion evaluation and correction for PET scans with ¹⁸F-FDG in the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) multi-center study. Ann Nucl Med 2012;26:535–44

    CrossRefPubMed
12. 12.↵
    1. Silverman DH,
    2. Mosconi L,
    3. Ercoli L,
    4. et al

    . Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Semin Nucl Med 2008;38:251–61

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Landis JR,
    2. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Lehman VT,
    2. Carter RE,
    3. Claassen DO,
    4. et al

    . Visual assessment versus quantitative three-dimensional stereotactic surface projection fluorodeoxyglucose positron emission tomography for detection of mild cognitive impairment and Alzheimer disease. Clin Nucl Med 2012;37:721–26

    CrossRefPubMed
15. 15.↵
    1. Foster NL,
    2. Heidebrink JL,
    3. Clark CM,
    4. et al

    . FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007;130(pt 10):2616–35

    Abstract/FREE Full Text
16. 16.↵
    1. Ishii K,
    2. Soma T,
    3. Kono AK,
    4. et al

    . Comparison of regional brain volume and glucose metabolism between patients with mild dementia with Lewy bodies and those with mild Alzheimer's disease. J Nucl Med 2007;48:704–11

    Abstract/FREE Full Text